{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:17:26Z","timestamp":1792761446942,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005643","name":"University of Lodz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.drudis.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T12:47:45Z","timestamp":1473770865000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?"],"prefix":"10.1016","volume":"22","author":[{"given":"Danina M.","family":"Muntean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Stasiolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Fabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Corina","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2016.09.001_bib0660","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.115.011646","article-title":"Association of serum lipids and coronary heart disease in contemporary observational studies","volume":"133","author":"Colantonio","year":"2016","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2016.09.001_bib0665","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2016.09.001_bib0670","doi-asserted-by":"crossref","first-page":"189525","DOI":"10.1155\/2015\/189525","article-title":"Complications of diabetes","volume":"2015","author":"Papatheodorou","year":"2015","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.drudis.2016.09.001_bib0675","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.drudis.2016.09.001_bib0680","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief."},{"key":"10.1016\/j.drudis.2016.09.001_bib0685","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0690","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0695","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3346\/jkms.2015.30.11.1612","article-title":"Application of new cholesterol guidelines to the Korean adult diabetic patients","volume":"30","author":"Kim","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib0700","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1060028014564181","article-title":"Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations","volume":"49","author":"Newsom","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2016.09.001_bib0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance \u2013 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib0710","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0715","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.jacc.2013.12.047","article-title":"Is myopathy the Achilles\u2019 heel of statins?: differences between the new cholesterol treatment guidelines and everyday clinical practice","volume":"63","author":"Rallidis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0720","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2016.09.001_bib0725","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drudis.2016.09.001_bib0730","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib0735","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0740","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0745","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists Collaboration","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2016.09.001_bib0750","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"issue":"3 Suppl.","key":"10.1016\/j.drudis.2016.09.001_bib0755","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0760","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12944-015-0169-0","article-title":"Lipids, blood pressure and kidney update 2015","volume":"14","author":"Banach","year":"2015","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.drudis.2016.09.001_bib0765","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0770","doi-asserted-by":"crossref","first-page":"562","DOI":"10.7326\/0003-4819-158-7-201304020-00010","article-title":"Statin discontinuation and intolerance: the challenge of lifelong therapy","volume":"158","author":"Grundy","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0775","first-page":"S35","article-title":"Diagnosis, prevention and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0780","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1074248414529622","article-title":"Addressing statin adverse effects in the clinic: the 5 Ms","volume":"19","author":"Katz","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib0785","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib0790","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0795","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2016.09.001_bib0800","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2013.07.001","article-title":"Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance","volume":"230","author":"Ballard","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib0805","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.atherosclerosis.2013.07.044","article-title":"STOMPing forward: statins, muscle complaints and CK","volume":"230","author":"Laaksonen","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib0810","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0815","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMp1112023","article-title":"Needed: pragmatic clinical trials for statin-intolerant patients","volume":"365","author":"Maningat","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0820","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2016.09.001_bib0825","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","article-title":"Statin myopathy: incidence, risk factors, and pathophysiology","volume":"9","author":"Sewright","year":"2007","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.drudis.2016.09.001_bib0830","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0835","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0840","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0845","doi-asserted-by":"crossref","first-page":"e2522","DOI":"10.1371\/journal.pone.0002522","article-title":"Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991\u20132006","volume":"3","author":"Molokhia","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2016.09.001_bib0850","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib0855","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"Group","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0860","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Collaborative Group","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2016.09.001_bib0865","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0870","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2016.09.001_bib0875","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.drudis.2016.09.001_bib0880","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1017\/cjn.2014.22","article-title":"Statin-associated autoimmune myopathies: a pathophysiologic spectrum","volume":"41","author":"Wu","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib0885","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.11.005","article-title":"Statins as a possible cause of inflammatory and necrotizing myopathies","volume":"222","author":"Padala","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib0890","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2006.07.033","article-title":"Impact of statin dosing intensity on transaminase and creatine kinase","volume":"120","author":"Dale","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib0895","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11536130-000000000-00000","article-title":"The risk for significant creatine kinase elevation with statins","volume":"10","author":"Stolcpart","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.drudis.2016.09.001_bib0900","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.drudis.2016.09.001_bib0905","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2015.03.025","article-title":"Genetic and immunologic susceptibility to statin-related myopathy","volume":"240","author":"Patel","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib0910","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","article-title":"Drug\u2013drug interactions that interfere with statin metabolism","volume":"11","author":"Hirota","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0915","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a \u2018mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0920","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2016.09.001_bib0925","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1388-1981(00)00139-6","article-title":"Peroxisomal protein targeting and identification of peroxisomal targeting signals in cholesterol biosynthetic enzymes","volume":"1529","author":"Olivier","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2016.09.001_bib0930","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-2275(20)41539-1","article-title":"HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes","volume":"33","author":"Williams","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drudis.2016.09.001_bib0935","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","article-title":"Molecular basis of statin-associated myopathy","volume":"202","author":"Vaklavas","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib0940","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects","volume":"78","author":"Mo\u00dfhammer","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0945","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0950","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/bmjdrc-2014-000017","article-title":"Statins impair glucose uptake in human cells","volume":"2","author":"Nowis","year":"2014","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.drudis.2016.09.001_bib0955","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0960","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib0965","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.110.975284","article-title":"Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia","volume":"123","author":"Stein","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2016.09.001_bib0970","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ab.2010.11.023","article-title":"Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling","volume":"410","author":"Aranibar","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.drudis.2016.09.001_bib0975","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/mus.20619","article-title":"Elevated skeletal muscle phosphodiesters in adults using statin medications","volume":"34","author":"Slade","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2016.09.001_bib0980","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1586\/14779072.6.7.971","article-title":"Statin myopathy as a metabolic muscle disease","volume":"6","author":"Phillips","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib0985","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2016.09.001_bib0990","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2016.09.001_bib0995","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1000","doi-asserted-by":"crossref","first-page":"e0128398","DOI":"10.1371\/journal.pone.0128398","article-title":"Statin-induced increases in atrophy gene expression occur independently of changes in PGC1alpha protein and mitochondrial content","volume":"10","author":"Goodman","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.drudis.2016.09.001_bib1005","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jcb.24077","article-title":"3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibition impairs muscle regeneration","volume":"113","author":"Trapani","year":"2012","journal-title":"J. Cell Biochem."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2016.09.001_bib1010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(15)60336-1","article-title":"Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach","volume":"385","author":"Bhandari","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2016.09.001_bib1015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","article-title":"Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle","volume":"24","author":"Bouitbir","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.drudis.2016.09.001_bib1020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.drudis.2016.09.001_bib1025","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.bbamcr.2015.03.006","article-title":"Reductive stress impairs myoblasts mitochondrial function and triggers mitochondrial hormesis","volume":"1853","author":"Singh","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2016.09.001_bib1030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations\u2014a systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2016.09.001_bib1035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drudis.2016.09.001_bib1040","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1045","first-page":"1047","article-title":"Futility of supplementation with Coenzyme Q10 for statin-induced myopathy: an updated (2015) meta-analysis of randomized controlled trials","volume":"36","author":"Banach","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2016.09.001_bib1050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio","volume":"42","author":"De Pinieux","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.taap.2012.06.020","article-title":"Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers","volume":"263","author":"Galtier","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1060","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.drudis.2016.09.001_bib1065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.drudis.2016.09.001_bib1070","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2016.09.001_bib1075","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib1080","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjp.2008.192","article-title":"Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres","volume":"154","author":"Sakamoto","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib1090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nbt1387","article-title":"Large-scale chemical dissection of mitochondrial function","volume":"26","author":"Wagner","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1095","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5\u2032-diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2016.09.001_bib1100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib1105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1110","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1161\/CIRCULATIONAHA.107.670588","article-title":"Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease","volume":"115","author":"Finck","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2016.09.001_bib1115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13105-015-0433-9","article-title":"Irisin, a unique non-inflammatory myokine in stimulating skeletal muscle metabolism","volume":"71","author":"Vaughan","year":"2015","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.drudis.2016.09.001_bib1120","doi-asserted-by":"crossref","first-page":"e72858","DOI":"10.1371\/journal.pone.0072858","article-title":"Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo","volume":"8","author":"Gouni-Berthold","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2016.09.001_bib1125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jacc.2012.08.1021","article-title":"Mitochondria as a therapeutic target in heart failure","volume":"61","author":"Bayeva","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MNH.0000000000000198","article-title":"Contribution of mitochondrial oxidative stress to hypertension","volume":"25","author":"Dikalov","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.drudis.2016.09.001_bib1135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.3998","article-title":"The metabolic regulation of aging","volume":"21","author":"Finkel","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib1140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1139\/bcb-2015-0012","article-title":"Targeting skeletal muscle mitochondria to prevent type 2 diabetes in youth","volume":"93","author":"Gordon","year":"2015","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ggi.12688","article-title":"Sarcopenia and frailty in older patients with diabetes mellitus","volume":"16","author":"Umegaki","year":"2016","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.drudis.2016.09.001_bib1150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.exger.2016.01.008","article-title":"Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age \u2013 an overview","volume":"76","author":"Buch","year":"2016","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trsl.2015.01.007","article-title":"Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy","volume":"166","author":"Suneja","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.drudis.2016.09.001_bib1160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1358863X14521315","article-title":"Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus","volume":"19","author":"Hartman","year":"2014","journal-title":"Vasc. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib1165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/CS20140101","article-title":"The Bioenergetic Health Index: a new concept in mitochondrial translational research","volume":"127","author":"Chacko","year":"2014","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib1170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.redox.2015.12.008","article-title":"The Bioenergetic Health Index is a sensitive measure of oxidative stress in human monocytes","volume":"8","author":"Chacko","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1180","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbagen.2013.09.010","article-title":"Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles","volume":"1840","author":"Simsek Ozek","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2016.09.001_bib1185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1998.8491","article-title":"Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study","volume":"152","author":"Nakahara","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib1195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1200","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.drudis.2016.09.001_bib1205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2353\/ajpath.2010.091140","article-title":"Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle","volume":"177","author":"Draeger","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1210","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1096\/fj.12-219345","article-title":"Annexin A1 is a biomarker of T-tubular repair in skeletal muscle of nonmyopathic patients undergoing statin therapy","volume":"27","author":"Voigt","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2016.09.001_bib1215","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mus.24722","article-title":"Skeletal muscle ultrastructure and function in statin-tolerant individuals","volume":"53","author":"Rengo","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2016.09.001_bib1220","doi-asserted-by":"crossref","first-page":"13823","DOI":"10.1038\/srep13823","article-title":"Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism","volume":"5","author":"Kain","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2016.09.001_bib1225","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"36","author":"Gambelli","year":"2004","journal-title":"J. Submicrosc. Cytol. Pathol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2004.06.014","article-title":"Statin myotoxicity is associated with changes in the cardiopulmonary function","volume":"177","author":"Phillips","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib1235","first-page":"422","article-title":"Mitochondrial quality control and muscle mass maintenance","volume":"6","author":"Romanello","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1240","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00406.2014","article-title":"The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects","volume":"309","author":"Izadpanah","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.drudis.2016.09.001_bib1250","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","article-title":"A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle","volume":"1","author":"Laaksonen","year":"2006","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2016.09.001_bib1255","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of statins on skeletal muscle: a perspective for physical therapists","volume":"90","author":"Di Stasi","year":"2010","journal-title":"Phys. Ther."},{"key":"10.1016\/j.drudis.2016.09.001_bib1260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2007.12.029","article-title":"The creatine kinase response to eccentric exercise with atorvastatin 10mg or 80mg","volume":"200","author":"Kearns","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2016.09.001_bib1265","first-page":"429","article-title":"The interaction between statins and exercise: mechanisms and strategies to counter the musculoskeletal side effects of this combination therapy","volume":"15","author":"Deichmann","year":"2015","journal-title":"Ochsner. J."},{"key":"10.1016\/j.drudis.2016.09.001_bib1270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tox.2009.10.014","article-title":"Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats","volume":"266","author":"Tonomura","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.drudis.2016.09.001_bib1275","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/toxsci\/kfv328","article-title":"Evaluation of the relative performance of drug-induced skeletal muscle injury biomarkers in rats","volume":"150","author":"Burch","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.drudis.2016.09.001_bib1280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tox.2012.07.012","article-title":"Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats","volume":"302","author":"Tonomura","year":"2012","journal-title":"Toxicology"},{"key":"10.1016\/j.drudis.2016.09.001_bib1285","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1545968305277167","article-title":"Underappreciated statin-induced myopathic weakness causes disability","volume":"19","author":"Dobkin","year":"2005","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.drudis.2016.09.001_bib1290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.21847","article-title":"Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications","volume":"43","author":"Wu","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2016.09.001_bib1295","article-title":"Evaluation of microRNAs-208 and 133a\/b as differential biomarkers of acute cardiac and skeletal muscle toxicity in rats","author":"Calvano","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1152\/japplphysiol.00654.2015","article-title":"Influence of statins on distinct circulating microRNAs during prolonged aerobic exercise","volume":"120","author":"Min","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.drudis.2016.09.001_bib1305","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archinte.163.6.688","article-title":"Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting","volume":"163","author":"Smith","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drudis.2016.09.001_bib1310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ab.2015.07.018","article-title":"Variability in microRNA recovery from plasma: comparison of five commercial kits","volume":"488","author":"Brunet-Vega","year":"2015","journal-title":"Anal. Biochem."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461630321X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461630321X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:29:35Z","timestamp":1761222575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964461630321X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S135964461630321X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2016.09.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}